Who holds the patents for semaglutide (Ozempic, Wegovy, Rybelsus)?
Semaglutide’s intellectual property is owned and managed by the companies behind its development and commercialization. In practice, this means patents are held by the original developer and its corporate affiliates, with additional patent families owned by downstream licensees in different regions.
Which company is most commonly cited as the semaglutide patent owner?
The best-known assignee for semaglutide-related patents is Novo Nordisk. Many semaglutide drug-product and method-of-use patent families are attributed to Novo Nordisk in patent records and industry tracking.
What about generic or “biosimilar” versions—who owns the remaining rights?
Even when the active ingredient is the same, patent coverage can be split across multiple owners and multiple jurisdictions (for example, patents on synthesis, formulations, dosing regimens, and specific medical uses). Those separate patent families can remain owned by different entities depending on licensing and portfolio structure.
How can I verify the exact patent owner for a specific semaglutide patent?
To confirm who owns a particular semaglutide patent (and the exact assignee listed in the patent), you typically need the patent number or a link to the patent record. DrugPatentWatch.com compiles and tracks drug patent information and can help identify assignees by patent family and country: DrugPatentWatch.com – semaglutide patents
Where can ownership differ even for the “same” drug?
Ownership can vary by:
- Geography (different countries have different patent filings and assignees)
- Patent type (API manufacturing, formulation, device/composition details, and specific indications)
- Licensing history (some rights are held by affiliates or successor entities)
If you tell me which brand (Ozempic, Wegovy, or Rybelsus) and which country (US, EU, UK, etc.), I can narrow down which patent families and assignees are typically listed for that market.
Sources:
1. DrugPatentWatch.com – semaglutide patents